Australia markets closed

    +23.80 (+0.31%)
  • ASX 200

    +9.90 (+0.13%)

    -0.0064 (-0.85%)
  • OIL

    +0.46 (+0.65%)
  • GOLD

    -10.90 (-0.61%)

    -2,735.66 (-5.67%)
  • CMC Crypto 200

    -51.42 (-5.47%)

    -0.0028 (-0.44%)

    +0.0009 (+0.09%)
  • NZX 50

    +10.73 (+0.09%)

    -114.22 (-0.81%)
  • FTSE

    -135.96 (-1.90%)
  • Dow Jones

    -533.37 (-1.58%)
  • DAX

    -279.63 (-1.78%)
  • Hang Seng

    +242.68 (+0.85%)
  • NIKKEI 225

    -54.25 (-0.19%)

Asia pacific antiviral drugs market size to amass USD 7.2 billion by 2027

·7-min read

The latest business intelligence report on ‘Asia Pacific Antiviral Drugs Market’ provides comprehensive insights about this industry sphere. It offers analysis of primary growth drivers, lucrative scenarios, limits, and challenges that will influence the market, dynamics during 2021-2027.

Selbyville, Delaware, May 17, 2021 (GLOBE NEWSWIRE) -- According to credible sources, Asia Pacific antiviral drugs market size is estimated to accumulate USD 7.2 billion by the year 2027, showcasing substantial growth. Exceptional increase in Covid-19 cases in China, India, and Australia, leading to rising hospitalization is the primary factor driving the market growth in APAC. Reportedly, around 25 million people in Asia were tested positive until mid-March 2021.

Moreover, the report encompasses a comparative study of bygone trends and present developments for the prediction of the industry expansion over 2021-2027. Lastly, the impact of COVID-19 pandemic is elaborated in the document to understand the commotions caused in the market sphere and enable stakeholders to take informed decisions.

Moreover, prevalence of infectious diseases, increase in instances of hospital-acquired infections, coupled with rising awareness related to treatment therapies are bolstering the demand for antiviral drugs in Asia pacific region. As stated by WHO, in China, over 87 million people chronic hepatitis B virus carriers. As reported by Chinese Center for Disease Control and Prevention, in 2018, over 400 people were ascertained to be HIV positive each day. As per WHO, in China over 1.25 million were infected with HIV in 2018.

Request Sample copy of this Report @

Additionally, favorable governmental policies & initiatives, alongside infrastructural development are further augmenting the market outlook. In India, in April 2017, the Ministry of Health and Family Welfare introduced a test-and-treat policy for HIV treatment.

Although, rising geriatric population with high susceptibility to infections, and HIV treatment product pipeline displays lucrative opportunities, but high cost of HIV as well as Hepatitis treatment, and drug resistance scenario will hamper the growth of Asia Pacific antiviral drugs industry.

Overview of market segmentations:

Based on types, Asia Pacific antiviral drug market is segmented into branded and generic. The report cites that generic segment was worth USD 1.5 billion in 2020 and is poised to grow further owing to rising consumer awareness about presence of generic drugs.

Speaking of age group, the marketplace is divided into pediatric, adult, and geriatric, wherein the adult segment accounted for 30% market share in 2020.

On the basis of indication, the industry is classified into HIV/AIDS, influenza, herpes simplex virus, hepatitis, and coronavirus infection among others. Of these, APAC antiviral drugs market share from HIV/AIDS segment was USD 3.2 billion in 2020, owing to rising cognizance of HIV treatment therapies.

Moving on to drug class, the market is fragmented into DNA polymerase inhibitors, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors including others. While proteases inhibitors segment accounted for 18% industry share in 2020, reserve transcriptase inhibitors segment held 40% share in the same year.

To access a sample copy or view this report in detail along with the table of contents, please click the link below:

Regional outlook:

As per expert verbatim, India antiviral drug market valuation is expected to reach USD 1.2 billion by 2027, owing to improved healthcare infrastructure. Similarly, China held a market share of 16% in 2020 and is reckoned to grow modestly through 2027, attributable to inflowing funding for research & development and enhancement of health infrastructure.

Asia Pacific Antiviral Drugs Market by Type (Revenue, USD Million, 2016-2027)

  • Branded

  • Generic

Asia Pacific Antiviral Drugs Market by Age Group (Revenue, USD Million, 2016-2027)

  • Pediatric

  • Adult

  • Geriatric

Asia Pacific Antiviral Drugs Market by Indication (Revenue, USD Million, 2016-2027)


  • Influenza

  • Herpes Simplex Virus

  • Hepatitis

  • Coronavirus Infection

  • others

Asia Pacific Antiviral Drugs Market by Drug Class (Revenue, USD Million, 2016-2027)

  • DNA polymerase inhibitors

  • Protease Inhibitors

  • Reverse Transcriptase Inhibitors

  • Neuraminidase Inhibitors

  • Others

Asia Pacific Antiviral Drugs Market Regional Terrain (Revenue, USD Million, 2016-2027)

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Thailand

  • Indonesia

  • Malaysia

  • Philippines

  • Australia

Asia Pacific Antiviral Drugs Market Competitive Outlook (Revenue, USD Million, 2016-2027)

  • Viatris Inc.

  • Sun Pharmaceutical Industries Ltd.

  • Cipla Ltd.

  • Aurobindo Pharma Limited

  • Bristol Myers Squibb

  • Merck & Co. Inc.

  • GlaxoSmithKline plc

  • AbbVie

  • Johnson & Johnson

  • Gilead Sciences Inc.

Table of Content:

Chapter 1 Methodology

1.1 Market definitions

1.2 Forecast assumptions

1.3 Data sources

1.3.1 Secondary Paid sources Unpaid sources

1.3.2 Primary

Chapter 2 Market Summary

2.1 Asia Pacific anti-viral drugs industry summary, 2016 - 2027

2.1.1 Country trends

2.1.2 Drug class trends

2.1.3 Indication trends

2.1.4 Type trends

2.1.5 Age group trends

Chapter 3 Market Analysis

3.1 Industry segmentation

3.2 Industry outlook, 2016 - 2027 (USD Million)

3.3 Major factor analysis

3.4 Analysis of COVID-19 impact on the industry

3.5 Porter's analysis

3.6 Competitive review, 2020

3.7 PEST analysis

Chapter 4 Asia Pacific Anti-viral Drugs Market, By Drug Class

4.1 Market trends

4.2 DNA polymerase inhibitors

4.2.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3 Reverse transcriptase inhibitors

4.3.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4 Protease inhibitors

4.4.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.5 Neuraminidase inhibitors

4.5.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.6 Others

4.6.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5 Asia Pacific Anti-viral Drugs Market, By Indication

5.1 Market trends

5.2 Influenza

5.2.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)


5.3.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.4 Hepatitis

5.4.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.5 Herpes Simplex Virus

Chapter 6 Asia Pacific Anti-viral Drugs Market, By Type

6.1 Market trends

6.2 Branded

6.2.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3 Generic

6.3.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7 Asia Pacific Anti-viral Drugs Market, By Age Group

7.1 Market trends

7.2 Adult

7.2.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3 Pediatric

7.3.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4 Geriatric

7.4.1 Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8 Asia Pacific Anti-viral Drugs Market, By Country

Related Report:

Antiviral Drugs Market Size, Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

The anti-viral drugs market is likely to witness exponential growth over the forecast time period owing to large patient pool suffering from COVID-19 infection, increasing prevalence of sexually transmitted diseases, and instances of seasonal flu across the U.S. Antiviral drugs are usually prescription medicines that efficiently fight against viruses in the body. These come in inhaled powder form, liquid form, and pills form. When utilized as directed, these drugs aid in reducing the duration of flu symptoms in otherwise healthy children as well as adults and might also reduce the danger of common flu symptoms.

Increasing CVOVID-19 cases across the world is further driving the demand for anti-viral drugs. As per mortality surveillance data of NCHS on 25th February 2021, nearly 19.3 per cent of the deaths that happened in the week ending 20th February 2021 were mainly because of COVID-19, influenza, and pneumonia. In fact, Remdesivir is the only anti-viral drug approved by the FDA for the treatment of SARS-CoV-2 virus or COVID-19.

About US:

Market Study Report, LLC. is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.

CONTACT: Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: News:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting